로딩 중…
StockDiggingStockDigging

Dr. Reddy's Laboratories Limited

RDY· NYSE
ININ
$12.20+0.04%
2026-09-18

Financials

Valuation Metrics

Dr. Reddy's Laboratories Limited's Market Cap is $10.18B. Ranked #909 of 3,121 in US market (top 29%), #619 of 1,658 on NYSE (top 37%), #44 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 17%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$10.18B
Revenue$3.77B
Net Income$376M
Total Assets$6.10B
Net Assets$4.06B
Employees27,527
Value
P/E27.10x
P/B2.51x
P/S2.70x
EV/EBITDA17.19x
FCF Yield1.69%
Profitability
ROE9.25%
ROA6.16%
Op. Margin10.57%
Revenue Growth-0.43%
Earnings Growth-41.61%
Financial Health
Debt Ratio49.18%
Total Debt$763M
FCF$172M
Cash$119M
Current Ratio1.90x
Net Debt/EBITDA1.02x
Dividend
Div. Yield0.75%
Div. Growth5.17%
Performance
1Y Return-17.77%
1M Return0.70%
From 52W High-22.18%
1Y MDD-26.01%
Trading
Volume1,492,592 shares
Trading Value$18M

Company Info

CEO Erez Israeli
Employees 27,527
HQ Hyderabad, IN

Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.